Sandy Macrae - 22 Apr 2025 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role: PRESIDENT, CEO AND DIRECTOR, Director
Signature: /s/ Prathyusha Duraibabu, Attorney-in-Fact
Issuer symbol: SGMO
Transactions as of: 22 Apr 2025
Net transaction value: -$98,551
Form type: 4
Filing time: 24 Apr 2025, 16:08:28 UTC
Previous filing: 26 Feb 2025
Next filing: 28 May 2025
SEC filing: View on sec.gov

Key filing fact

Sandy Macrae filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 24 Apr 2025.

Key facts

This page summarizes Sandy Macrae's Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
1 reported transaction and 0 derivative rows are listed below.
Filing timestamp: 24 Apr 2025, 16:08.

Change

Previous filing in this sequence was filed on 26 Feb 2025.
Current net transaction value: -$98,551.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reported transactions

SGMO transaction

Common Stock

Tax liability

Transaction value: $98,551
Shares: -126,950
Change %: -5.2%
Price: $0.7763
Shares after: 2,325,898
Date: 22 Apr 2025
Ownership: Direct
Footnotes: F1, F2

^* indicates a reported price that failed the local validity check.

Explanation of Responses:

Id	Content
F1	Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on April 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on April 22, 2025 of $0.7763/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F2	Includes: (a) 123,050 shares resulting from the April 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 750,000 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 58,988 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Content

Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on April 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on April 22, 2025 of $0.7763/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

Includes: (a) 123,050 shares resulting from the April 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 750,000 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 58,988 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.